Shots:
- Pfizer has reported P-II (FOURLIGHT-1) trial data assessing atirmociclib + fulvestrant vs fulvestrant or everolimus plus exemestane in 264 pts with HR+, HER2- advanced or metastatic breast cancer who had received prior CDK 4/6 inhibitor-based treatment
- Trial met its 1EP, showing improved PFS as assessed by the investigator, with benefit consistent across all subgroups. OS (2EP) was immature during analysis, with ~20% of pts having an event
- Additionally, a P-III registrational study of Atirmociclib in the 1L metastatic setting is ongoing, with results from a P-II neoadjuvant study in Early Breast Cancer to be presented at a future medical meeting
Ref: Pfizer | Image: Pfizer | Press Release
Related News: Pfizer Reports Topline P-II Trial Data on Tilrekimig in Moderate to Severe Atopic Dermatitis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
